₹
35.40
Dec 24
Business Description
Beryl Drugs Ltd
ISIN : INE415H01017
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.06 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.49 | |||||
Debt-to-EBITDA | 1.92 | |||||
Interest Coverage | 1.49 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 3.32 | |||||
Beneish M-Score | -2.44 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 24.1 | |||||
3-Year EBITDA Growth Rate | 9.1 | |||||
3-Year FCF Growth Rate | 9.4 | |||||
3-Year Book Growth Rate | 4 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 28.11 | |||||
9-Day RSI | 41.31 | |||||
14-Day RSI | 45.81 | |||||
6-1 Month Momentum % | -3.48 | |||||
12-1 Month Momentum % | 41.84 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.91 | |||||
Quick Ratio | 1.64 | |||||
Cash Ratio | 0.06 | |||||
Days Inventory | 25.42 | |||||
Days Sales Outstanding | 130.87 | |||||
Days Payable | 45.84 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -0.32 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 23.42 | |||||
Operating Margin % | 3.78 | |||||
Net Margin % | 1.53 | |||||
FCF Margin % | -2.4 | |||||
ROE % | 3.73 | |||||
ROA % | 1.89 | |||||
ROIC % | 3.42 | |||||
ROC (Joel Greenblatt) % | 8.93 | |||||
ROCE % | 9.32 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 52.84 | |||||
PE Ratio without NRI | 52.84 | |||||
Shiller PE Ratio | 37.94 | |||||
PEG Ratio | 3.83 | |||||
PS Ratio | 0.81 | |||||
PB Ratio | 1.93 | |||||
Price-to-Tangible-Book | 1.93 | |||||
Price-to-Operating-Cash-Flow | 21.9 | |||||
EV-to-EBIT | 19.88 | |||||
EV-to-EBITDA | 9.43 | |||||
EV-to-Revenue | 1 | |||||
EV-to-FCF | -44.17 | |||||
Price-to-Median-PS-Value | 2.07 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.12 | |||||
Price-to-Graham-Number | 2.13 | |||||
Price-to-Net-Current-Asset-Value | 14.22 | |||||
Earnings Yield (Greenblatt) % | 5.03 | |||||
FCF Yield % | -2.96 | |||||
Forward Rate of Return (Yacktman) % | 8.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Beryl Drugs Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₹) | 221.785 | ||
EPS (TTM) (₹) | 0.67 | ||
Beta | 0.23 | ||
Volatility % | 68.31 | ||
14-Day RSI | 45.81 | ||
14-Day ATR (₹) | 3.263468 | ||
20-Day SMA (₹) | 36.017 | ||
12-1 Month Momentum % | 41.84 | ||
52-Week Range (₹) | 22.09 - 46 | ||
Shares Outstanding (Mil) | 5.07 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Beryl Drugs Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Beryl Drugs Ltd Stock Events
Event | Date | Price(₹) | ||
---|---|---|---|---|
No Event Data |
Beryl Drugs Ltd Frequently Asked Questions
What is Beryl Drugs Ltd(BOM:524606)'s stock price today?
When is next earnings date of Beryl Drugs Ltd(BOM:524606)?
Does Beryl Drugs Ltd(BOM:524606) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |